Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system - PubMed (original) (raw)
Review
Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system
B V Zlokovic et al. Neurosurgery. 1997 Apr.
Abstract
Different vector systems that have been used and/or specifically developed for central nervous system (CNS) gene transfer studies are briefly discussed along with their advantages and disadvantages with respect to potential clinical application. These include retroviruses, recombinant herpes simplex virus, adenoviruses, adenoassociated viruses, encapsulation of plasmid deoxyribonucleic acid into cationic liposomes, and neural and oliogodendroglial stem cells. Particular attention has been paid to relate the modality of a specific CNS gene therapy to the strategy for adequate delivery of genetic material to the brain for either global or localized CNS neurodegenerative chronic disorder, as well as for CNS tumors and stroke. Techniques to circumvent the "impermeable" blood-brain barrier and how to breach the more versatile blood-brain-tumor barrier to deliver the genetic material to the target CNS cells are reviewed and include the following: 1) local stereotactic CNS injection/infusion of viral vectors, administration of vector producer cells, or cell replacement; 2) local administration of genetic material into the cerebrospinal fluid ventriculocisternal system; 3) osmotic opening of the blood-brain barrier; 4) local intra-arterial infusion; and 5) administration of blood-brain-tumor barrier permeabilizers, such as a bradykinin B2 agonist RMP-7. It is concluded that gene therapy for several brain disorders holds great potential, as suggested mainly by in vitro experiments and, to some extent, by a limited number of animal experiments. However, several drawbacks currently hamper the application of gene therapy under the clinical setting. The problems associated with gene therapy that still present major obstacles are as follows: 1) inefficient transfection of host cells by viral vectors; 2) restricted delivery of genetic material across vascular barriers of the CNS and brain tumors; 3) nonselective expression of the transgene; and 4) in situ CNS regulation of the transgene expression in a therapeutically controlled manner, as imposed by the course and phenotype of the CNS disease.
Similar articles
- Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system.
Zlokovic BV, Apuzzo ML. Zlokovic BV, et al. Neurosurgery. 1997 Apr;40(4):789-803; discussion 803-4. doi: 10.1097/00006123-199704000-00027. Neurosurgery. 1997. PMID: 9092853 Review. - Endovascular restorative neurosurgery: a novel concept for molecular and cellular therapy of the nervous system.
Amar AP, Zlokovic BV, Apuzzo ML. Amar AP, et al. Neurosurgery. 2003 Feb;52(2):402-12; discussion 412-3. doi: 10.1227/01.neu.0000043698.86548.a0. Neurosurgery. 2003. PMID: 12535371 - Liposomal and viral vectors for gene therapy of the central nervous system.
de Lima MC, da Cruz MT, Cardoso AL, Simoes S, de Almeida LP. de Lima MC, et al. Curr Drug Targets CNS Neurol Disord. 2005 Aug;4(4):453-65. doi: 10.2174/1568007054546144. Curr Drug Targets CNS Neurol Disord. 2005. PMID: 16101560 Review. - Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors.
Scarpini CG, May J, Lachmann RH, Preston CM, Dunnett SB, Torres EM, Efstathiou S. Scarpini CG, et al. Gene Ther. 2001 Jul;8(14):1057-71. doi: 10.1038/sj.gt.3301497. Gene Ther. 2001. PMID: 11526453 - Crossing the blood-brain-barrier with viral vectors.
Fu H, McCarty DM. Fu H, et al. Curr Opin Virol. 2016 Dec;21:87-92. doi: 10.1016/j.coviro.2016.08.006. Epub 2016 Sep 1. Curr Opin Virol. 2016. PMID: 27591676 Review.
Cited by
- Natural Compounds in Liposomal Nanoformulations of Potential Clinical Application in Glioblastoma.
Piwowarczyk L, Mlynarczyk DT, Krajka-Kuźniak V, Majchrzak-Celińska A, Budzianowska A, Tomczak S, Budzianowski J, Woźniak-Braszak A, Pietrzyk R, Baranowski M, Goslinski T, Jelinska A. Piwowarczyk L, et al. Cancers (Basel). 2022 Dec 16;14(24):6222. doi: 10.3390/cancers14246222. Cancers (Basel). 2022. PMID: 36551708 Free PMC article. - A New Method for the Visualization of Living Dopaminergic Neurons and Prospects for Using It to Develop Targeted Drug Delivery to These Cells.
Blokhin V, Lavrova AV, Surkov SA, Mingazov ER, Gretskaya NM, Bezuglov VV, Ugrumov MV. Blokhin V, et al. Int J Mol Sci. 2022 Mar 27;23(7):3678. doi: 10.3390/ijms23073678. Int J Mol Sci. 2022. PMID: 35409040 Free PMC article. - Influences of HIF-lα on Bax/Bcl-2 and VEGF expressions in rats with spinal cord injury.
Chen MH, Ren QX, Yang WF, Chen XL, Lu C, Sun J. Chen MH, et al. Int J Clin Exp Pathol. 2013 Oct 15;6(11):2312-22. eCollection 2013. Int J Clin Exp Pathol. 2013. PMID: 24228092 Free PMC article. - Drug delivery systems for the treatment of ischemic stroke.
Rhim T, Lee DY, Lee M. Rhim T, et al. Pharm Res. 2013 Oct;30(10):2429-44. doi: 10.1007/s11095-012-0959-2. Epub 2013 Jan 10. Pharm Res. 2013. PMID: 23307348 Review. - Clinical development of experimental therapies for malignant glioma.
Rainov NG, Heidecke V. Rainov NG, et al. Sultan Qaboos Univ Med J. 2011 Feb;11(1):5-28. Epub 2011 Feb 12. Sultan Qaboos Univ Med J. 2011. PMID: 21509204 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical